Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial

on behalf of the YOSEMITE and RHINE Investigators

doi:10.1007/s10384-023-00979-8

Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial

on behalf of the YOSEMITE and RHINE Investigators

Ophthalmology

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	264-279
Number of pages	16
Journal	Japanese Journal of Ophthalmology
Volume	67
Issue number	3
DOIs	https://doi.org/10.1007/s10384-023-00979-8
State	Published - May 2023

ASJC Scopus Subject Areas

Ophthalmology

Keywords

Angiopoietin-2
Anti-VEGF therapy
Diabetic macular edema
Faricimab
Vascular stability

Access to Document

10.1007/s10384-023-00979-8

OpenUrl availability

Full text

Cite this

Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial. / on behalf of the YOSEMITE and RHINE Investigators.
In: Japanese Journal of Ophthalmology, Vol. 67, No. 3, 05.2023, p. 264-279.

Research output: Contribution to journal › Article › peer-review

on behalf of the YOSEMITE and RHINE Investigators 2023, 'Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial', Japanese Journal of Ophthalmology, vol. 67, no. 3, pp. 264-279. https://doi.org/10.1007/s10384-023-00979-8

@article{f1257621d3c947a39d3b9048554ba963,

title = "Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial",

keywords = "Angiopoietin-2, Anti-VEGF therapy, Diabetic macular edema, Faricimab, Vascular stability",

author = "{on behalf of the YOSEMITE and RHINE Investigators} and Masahiko Shimura and Shigehiko Kitano and Nahoko Ogata and Yoshinori Mitamura and Hideyasu Oh and Haruka Ochi and Shino Ohsawa and Akito Hirakata and Matthias Bolz and Oliver Findl and Andreas Pollreisz and Martin Weger and Vesselin Daskalov and Aneta Misheva and Iva Petkova and Guneva, {Daniela Tosheva} and Petja Vassileva and Cornut, {Pierre Loic} and Korobelnik, {Jean Francois} and Olivier Lebreton and Ramin Tadayoni and Nicole Eter and Nicolas Feltgen and Carsten Framme and Katrin Lorenz and Georg Spital and Gyorgy Bator and Andr{\'a}s Seres and Lajos Szalczer and Edit Toth-Molnar and Attila Vajas and Balazs Varsanyi and Michaella Goldstein and Jaime Levy and Haia Morori-Katz and Irit Rosenblatt and Barak Yoreh and Francesco Bandello and Carlo Cagini and Leonardo Mastropasqua and Massimo Nicolo and Parravano, {Maria Cristina} and Francesco Viola and Akira Fukutomi and Ken Hayashi and Akito Hirakata and Shigeru Honda and Yasuhiro Ikeda and Yasuki Ito and Clement Chan",

note = "Publisher Copyright: {\textcopyright} 2023, Japanese Ophthalmological Society.",

year = "2023",

month = may,

doi = "10.1007/s10384-023-00979-8",

language = "English",

volume = "67",

pages = "264--279",

journal = "Japanese Journal of Ophthalmology",

issn = "0021-5155",

number = "3",

}

TY - JOUR

T1 - Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema

T2 - 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial

AU - on behalf of the YOSEMITE and RHINE Investigators

AU - Shimura, Masahiko

AU - Kitano, Shigehiko

AU - Ogata, Nahoko

AU - Mitamura, Yoshinori

AU - Oh, Hideyasu

AU - Ochi, Haruka

AU - Ohsawa, Shino

AU - Hirakata, Akito

AU - Bolz, Matthias

AU - Findl, Oliver

AU - Pollreisz, Andreas

AU - Weger, Martin

AU - Daskalov, Vesselin

AU - Misheva, Aneta

AU - Petkova, Iva

AU - Guneva, Daniela Tosheva

AU - Vassileva, Petja

AU - Cornut, Pierre Loic

AU - Korobelnik, Jean Francois

AU - Lebreton, Olivier

AU - Tadayoni, Ramin

AU - Eter, Nicole

AU - Feltgen, Nicolas

AU - Framme, Carsten

AU - Lorenz, Katrin

AU - Spital, Georg

AU - Bator, Gyorgy

AU - Seres, András

AU - Szalczer, Lajos

AU - Toth-Molnar, Edit

AU - Vajas, Attila

AU - Varsanyi, Balazs

AU - Goldstein, Michaella

AU - Levy, Jaime

AU - Morori-Katz, Haia

AU - Rosenblatt, Irit

AU - Yoreh, Barak

AU - Bandello, Francesco

AU - Cagini, Carlo

AU - Mastropasqua, Leonardo

AU - Nicolo, Massimo

AU - Parravano, Maria Cristina

AU - Viola, Francesco

AU - Fukutomi, Akira

AU - Hayashi, Ken

AU - Hirakata, Akito

AU - Honda, Shigeru

AU - Ikeda, Yasuhiro

AU - Ito, Yasuki

AU - Chan, Clement

PY - 2023/5

Y1 - 2023/5

KW - Angiopoietin-2

KW - Anti-VEGF therapy

KW - Diabetic macular edema

KW - Faricimab

KW - Vascular stability

UR - http://www.scopus.com/inward/record.url?scp=85159762158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85159762158&partnerID=8YFLogxK

U2 - 10.1007/s10384-023-00979-8

DO - 10.1007/s10384-023-00979-8

M3 - Article

C2 - 36897413

AN - SCOPUS:85159762158

SN - 0021-5155

VL - 67

SP - 264

EP - 279

JO - Japanese Journal of Ophthalmology

JF - Japanese Journal of Ophthalmology

IS - 3

ER -

Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial

ASJC Scopus Subject Areas

Keywords

Access to Document

OpenUrl availability

Other files and links

Cite this